Islets beta-cell function and usefulness of sulfonylureas in glycemic control in type 2 diabetic patients with sulfonylurea failure.

Not Applicable

Completed

• Conditions: one; Sulfonylurea failure; Type 2 DM

• Registration Number: TCTR20170525001
• Lead Sponsor: one

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2009-02-02
• Study Start: 2017-05-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Type 2 diabetic patients who had sulfonylurea failure. Sulfonylurea failure defined by the presence of hemoglobin A1C levels of >8% for longer than 6 months during treatment with combination of recommended maximum dosages of an SU and metformin.

Exclusion Criteria

Currently treated with insulin and dipeptidyl peptidase-4 (DPP-4) inhibitors, glucocorticoid therapy, acute illnesses and infections, serum creatinine levels of >1.5 mg/dL, and serum aspartate transferase (AST) and/or alanine transferase (ALT) levels of >3 times higher than the upper limit of normal ranges, and history of diabetic ketoacidosis or hyperglycemic hyperosmolar non-ketotic state.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To examine islets beta-cell function and usefulness of SU in type 2 diabetic patients who could not During taking sulfonulurea and stop taking sulfonylurea Beta cell function and insulin resistance assess by OGTT

Secondary Outcome Measures

Name	Time	Method
one None None